Neuphoria Therapeutics Inc (NEUP)

$4.27 +0.08 (1.91%)
Market Cap 23.50M
Revenue (ttm) 15.65M
Net Income (ttm) -370,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2.36%
Debt to Equity Ratio 0.00
Volume 74,300
Avg Vol 1,972,444
Day's Range N/A - N/A
Shares Out 5.38M
Stochastic %K 34%
Beta 0.51
Analysts Strong Sell
Price Target $20.50

Company Profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 439 5551
Address:
100 Summit Drive, Burlington, United States
JohnTrack
JohnTrack Dec. 4 at 2:34 PM
$NEUP waiting for spark!!
0 · Reply
JohnTrack
JohnTrack Dec. 4 at 1:13 PM
$NEUP lowball offer, nope! https://www.rapidticker.com/news/neup-neuphoria-responds-to-lynx1s-revised-98aeaf
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Dec. 3 at 6:26 PM
$NEUP Do you work for Lynx1? Sounds like it.
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Dec. 3 at 6:18 PM
$NEUP Reversal Time
1 · Reply
guidoschini
guidoschini Dec. 3 at 4:53 PM
$NEUP dead title
0 · Reply
Stmkr
Stmkr Dec. 3 at 4:07 AM
$NEUP What a mess tbis back-amd -forth betweem NEUP and Lynx1. Very dissapointed by the mamagement's handling of the situation
0 · Reply
guidoschini
guidoschini Dec. 3 at 12:10 AM
$NEUP NEUP will soon go much lower. He doesn't react anymore
0 · Reply
Stmkr
Stmkr Dec. 2 at 1:33 PM
$NEUP Lol. ridiculous "On December 2, 2025, the Reporting Persons delivered a letter to the Board which contained a new non-binding proposal (the "Recalculated Initial Offer") to acquire, through one or more managed investment funds and vehicles affiliated with the Investment Manager, all of the outstanding shares of capital stock of the Company for a price of $4.75 per share in cash."
0 · Reply
guidoschini
guidoschini Dec. 1 at 11:42 PM
$NEUP The descent continues without end
0 · Reply
frontiere
frontiere Dec. 1 at 3:00 PM
$NEUP Neuphoria ex $BNOX Bionomics ref=$4.50 — NO PSTN since before the SAD readout 👇 but watching the drama w Lynx1 vs NEUP activist campaign. Very interesting table in the PR. https://lifesciencereport.com/news/nasdaq/neup/neuphoria-provides-facts-exposes-false-narratives-in-response-to-lynx1-fictions
0 · Reply
Latest News on NEUP
Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Dec 4, 2025, 8:00 AM EST - 16 hours ago

Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Dec 1, 2025, 8:00 AM EST - 3 days ago

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Nov 24, 2025, 8:00 AM EST - 10 days ago

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Nov 11, 2025, 7:00 AM EST - 23 days ago

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

Oct 27, 2025, 4:29 PM EDT - 5 weeks ago

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Oct 21, 2025, 8:16 AM EDT - 6 weeks ago

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

CTXR PCAR

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Oct 20, 2025, 4:15 PM EDT - 6 weeks ago

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Sep 29, 2025, 4:54 PM EDT - 2 months ago

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Sep 4, 2025, 7:00 AM EDT - 3 months ago

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 4:05 PM EDT - 3 months ago

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 27, 2025, 4:10 PM EDT - 6 months ago

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Neuphoria Provides First Quarter 2025 Business Updates

May 20, 2025, 4:22 PM EDT - 7 months ago

Neuphoria Provides First Quarter 2025 Business Updates

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Apr 15, 2025, 8:00 AM EDT - 8 months ago

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Mar 3, 2025, 7:30 AM EST - 9 months ago

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Feb 12, 2025, 7:00 AM EST - 10 months ago

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

Dec 23, 2024, 4:49 PM EST - 1 year ago

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

JohnTrack
JohnTrack Dec. 4 at 2:34 PM
$NEUP waiting for spark!!
0 · Reply
JohnTrack
JohnTrack Dec. 4 at 1:13 PM
$NEUP lowball offer, nope! https://www.rapidticker.com/news/neup-neuphoria-responds-to-lynx1s-revised-98aeaf
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Dec. 3 at 6:26 PM
$NEUP Do you work for Lynx1? Sounds like it.
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Dec. 3 at 6:18 PM
$NEUP Reversal Time
1 · Reply
guidoschini
guidoschini Dec. 3 at 4:53 PM
$NEUP dead title
0 · Reply
Stmkr
Stmkr Dec. 3 at 4:07 AM
$NEUP What a mess tbis back-amd -forth betweem NEUP and Lynx1. Very dissapointed by the mamagement's handling of the situation
0 · Reply
guidoschini
guidoschini Dec. 3 at 12:10 AM
$NEUP NEUP will soon go much lower. He doesn't react anymore
0 · Reply
Stmkr
Stmkr Dec. 2 at 1:33 PM
$NEUP Lol. ridiculous "On December 2, 2025, the Reporting Persons delivered a letter to the Board which contained a new non-binding proposal (the "Recalculated Initial Offer") to acquire, through one or more managed investment funds and vehicles affiliated with the Investment Manager, all of the outstanding shares of capital stock of the Company for a price of $4.75 per share in cash."
0 · Reply
guidoschini
guidoschini Dec. 1 at 11:42 PM
$NEUP The descent continues without end
0 · Reply
frontiere
frontiere Dec. 1 at 3:00 PM
$NEUP Neuphoria ex $BNOX Bionomics ref=$4.50 — NO PSTN since before the SAD readout 👇 but watching the drama w Lynx1 vs NEUP activist campaign. Very interesting table in the PR. https://lifesciencereport.com/news/nasdaq/neup/neuphoria-provides-facts-exposes-false-narratives-in-response-to-lynx1-fictions
0 · Reply
Rufusbird
Rufusbird Nov. 28 at 7:05 PM
$NEUP Linx1 is the shareholders friend: s Todays new SEC filing 13D/A and see what the accomplished for shareholders: Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On November 25, 2025, the Company disclosed that it ceased its dilutive issuances of securities under its at-the-market ("ATM") offering program on November 7, 2025, the last business day prior to our nomination of director candidates and submission of our prior offer to acquire the Company for $5.20 per share (the "Initial Offer")... . As a result of the Company's disclosure that it has ceased issuing shares, we are in the process of recalculating and resubmitting a revised offer based on the assumption that no further issuances will occur during the pendency of the strategic review and incorporating the economics of these value-destructive stock issuances. https://www.sec.gov/Archives/edgar/data/1191070/000090514825004191/xslSCHEDULE_13D_X01/primary_doc.xml
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Nov. 28 at 2:41 PM
$NEUP and that is what @rufusbird wants us to vote "for". Is he a fake BULL ???
0 · Reply
Stmkr
Stmkr Nov. 28 at 2:38 PM
$NEUP So Lynx plans to make an even lower offer for acquisition. Lol Is he serious? Noone will accept $5.2, let alone lower
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Nov. 28 at 2:24 PM
$NEUP Stop Lying ====>
0 · Reply
guidoschini
guidoschini Nov. 28 at 1:38 PM
$NEUP The stock continues to lose value and is now unable to reverse the trend
0 · Reply
Rufusbird
Rufusbird Nov. 27 at 9:11 PM
$NEUP why ? because look at what NEUP did to the stock price after issuing 2 million shares using Wainwright ATM in the past 3 weeks. If someone comes up with a better offer, NEUP has to tell shareholders. Which the share dilution makes the company less attractive to a buyer. What is to stop them from further dilution. A vote in two weeks could put a stop to it. Even Linx1 would benefit from another higher offer for the shares.
0 · Reply
Rufusbird
Rufusbird Nov. 27 at 9:05 PM
$NEUP read the most important filing. Linx1 DFAN14A https://www.sec.gov/Archives/edgar/data/1191070/000119312525300651/d95937ddfan14a.htm and vote out the Neuphora boards banker director . the Linx1 new filings show exactly why.
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Nov. 27 at 9:02 PM
$NEUP Dude, they low balled us for $5.20. Are you kidding me❓ Why would any share holder vote for LYNX1 after seeing that ❓
0 · Reply
CANITBTHISEZTOMAKEMONEY
CANITBTHISEZTOMAKEMONEY Nov. 27 at 7:05 PM
$NEUP Don't vote for Lynx1, obviously. I wonder what the new evaluation will come up with ❓
2 · Reply
Rufusbird
Rufusbird Nov. 26 at 11:05 PM
$NEUP vote for Linx1 directors: this is totally uacceptable by one of NEUP's directors:
2 · Reply
Rufusbird
Rufusbird Nov. 26 at 11:04 PM
$NEUP
0 · Reply
guidoschini
guidoschini Nov. 26 at 3:49 PM
$NEUP down down down
0 · Reply